|
Faculty
Dennis Burton
Professor
Immunology and Microbial Science
TSRI - 1989
Joint Appointments
Department of Molecular Biology
The Ragon Institute of MGH, MIT and Harvard
Education
University of Oxford, United Kingdom, B.A. Oxon 1st Class, 1974
Ph.D., University of Lund, Sweden, 1978
Awards & Activities
Positions and Honors
1991- Professor: The Scripps Research Institute, La Jolla, CA.
1990-1991 Personal Chair: University of Sheffield, UK.
1989-1991 Visiting Member: Research Institute of Scripps Clinic, La Jolla, CA
1987-1990 Senior Lecturer in Biochemistry: University of Sheffield, UK.
1981-1987 Lecturer in Biochemistry: University of Sheffield, UK
1979-1981 Medical Research Council Training Fellowship: University of Oxford, UK
Scientific Awards and Other Professional Activities
2009-2019 NIH Merit Award
2009 Eli Lilly Lecturer, American Society for Virology, 28th Annual Meeting Symposia
2009-present Steering Committee, Ragon Institute of MGH, MIT and Harvard
2008 Pfizer Visiting Professorship in Infectious Diseases, Visiting Professor at Vanderbilt University Medical Center
2008-present Science Committee, Global HIV Vaccine Enterprise
2008-present Visiting Professor, Oxford Centre in Virology, Oxford, UK
2008-present NIH AIDS Vaccine Research Subcommittee (AVRS)
2007 Thomas J. Matthews Lectureship, Duke University
2006 First Distinguished Lecture in Virology, Oxford
2005-present Member, American Academy of Microbiology
2005-present Executive Committee, The Center for AIDS Research (CFAR), University of California, San Diego
2003-present HIV-1 Vaccine Trials Network (HVTN) Laboratory Scientific Advisory Committee, NIH
2002-present Director, IAVI Neutralizing Antibody Consortium
2002-present American Foundation for AIDS Research Basic Science Committee (amfAR)
2001-2004 IAVI Scientific Advisory Committee
1995-2005 NIH Merit Award
1995-2000 Member, NIH Study Section, AIDS and Related Research
1985-1991 Jenner Fellow: Lister Institute of Preventive Medicine
Research Focus
Antibodies and Infectious Disease
The perception of man as the easy victor over microbes has changed dramatically in the last two decades. Vaccination has offered protection against a number of viral pathogens, but it is increasingly recognized that the strategies used in the past will not be successful against all viruses. More understanding of viral pathogenesis and the interaction of viruses with the immune system is required. We are focused on the interplay of antibodies and viruses in humans, and it particular, the highly mutable viruses, human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). We have developed broadly neutralizing antibodies to these viruses to explore the anti-viral activity of antibodies in vitro and in vivo and to define molecular targets for rational vaccine design.
Selected References
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 Sep 6;449(7158):101-4. PMID: 17805298.
Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature Medicine. 2008 Jan;14(1):25-7. PMID: 18064037.
Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008 May 9;320(5877):760-4. PMID: 18467582.
Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. PMID: 19436712.
|
